Welcome to the Men's Health Knowledge Centre

As a disease topic Men's Health covers a broad set of issues affecting men of all ages. Some of the issues requiring greater focus and more thorough dissemination of information amongst the healthcare community, are those that have the potential to go undetected in the early stages. These include, hypogonadism and erectile dysfunction.

Early detection and more regular health checks of these diseases, not only improve prognosis and efficacy of treatment outcomes, but also quality of life.

Latest Updates

  • July 2014 - Effects of testosterone deficiency on body composition, strength and sexual function in men, and the tolerability of long-acting testosterone undecanoate in daily clinical practice

    Key Points

    • The randomized controlled study showed that there is considerable variation in the dose of testosterone required to prevent adverse changes in body composition, strength and sexual function
      • Only the highest dose of testosterone (10 g) achieved levels sufficient to reduce body fat
    • In this experimental study, administration of an aromatase inhibitor allowed the effects of testosterone and estrogen to be distinguished
      • Decreases in total-body lean mass, thigh-muscle area and leg-press strength were attributed to testosterone deficiency
      • Estrogen deficiency played a role in the increases in body fat
    • Both testosterone and estradiol are needed for maintenance of normal sexual function
    • Interpretation and treatment of hypogonadism in men should be individualized
    • In IPASS, TU was well tolerated in men with hypogonadism, and ADRs were rare (5.8%)
    • Increases in hematocrit and PSA, and injection site pain were the most common ADRs occurring in <1% of patients
    • Treatment-related ADRs lead to discontinuation in 31 men
    • Marked improvements in overall levels of sexual desire/libido were observed with TU
    • At the fifth injection of TU there was a significant decrease in waist circumference (p≤0.003), and a slight decrease in body weight

 

  • July 2014 - Testosterone treatment in men with osteoporosis and subnormal serum testosterone levels

    Key Points

    • This is the first long-term (6-year follow-up) study of men with osteoporosis treated with testosterone undecanoate (TU) 1,000 mg
    • In total, 45 men with osteoporosis and diagnosed with testosterone deficiency, aged between 40–68 years, were investigated
    • Most patients had been referred by an orthopedic clinic where serum testosterone levels were routinely monitored in patients with osteoporosis, especially in relatively young men
    • Many of the patients in this study were subsequently diagnosed with Klinefelter’s syndrome which had previously been undiagnosed
    • Other underlying causes of osteoporosis in patients included in this study were other forms of primary hypogonadism, alcohol abuse and Crohn’s disease
    • TU significantly and progressively improved bone mineral density (BMD) over 6 years
    • BMD, expressed as T-score measurements of the spine (L2–4) and femoral neck, significantly improved over 6 years compared with baseline and each year compared with the previous year (p<0.0001)
    • At the end of the observation time, patients were reclassified as having osteopenia rather than osteoporosis
    • Measures of blood pressure, metabolic parameters and levels of inflammatory biomarkers were significantly improved after 6 years

 

Access the Men's Health Knowledge Centre
Men's Health Knowledge Centre

View etiology, diagnosis and treatment options for hypogonadism and erectile dysfunction as well as a bimonthly updates section.

This information is intended for healthcare professionals only.If you are not a healthcare professional please visit our patient website